159 related articles for article (PubMed ID: 20233612)
21. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis.
Fan TM; de Lorimier LP; Garrett LD; Lacoste HI
J Vet Intern Med; 2008; 22(2):380-7. PubMed ID: 18346146
[TBL] [Abstract][Full Text] [Related]
22. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone.
El-Abdaimi K; Ste-Marie LG; Papavasiliou V; Dion N; Cardinal PE; Huang D; Kremer R
Int J Oncol; 2003 Apr; 22(4):883-90. PubMed ID: 12632083
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of zoledronate against neuroblastoma.
Dickson PV; Hamner JB; Cauthen LA; Ng CY; McCarville MB; Davidoff AM
Surgery; 2006 Aug; 140(2):227-35. PubMed ID: 16904974
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
van Beek ER; Lowik CW; van Wijngaarden J; Ebetino FH; Papapoulos SE
Breast Cancer Res Treat; 2009 Nov; 118(2):307-13. PubMed ID: 18989771
[TBL] [Abstract][Full Text] [Related]
26. [Effect and mechanism of gene therapy of lentivirus mediated RhoA shRNA on ovarian cancer xenograft in vivo].
Jiang WY; Kang JL; Wang XX; Yang WJ; Nie ML; Zhou C
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):778-83. PubMed ID: 24406137
[TBL] [Abstract][Full Text] [Related]
27. Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model.
Power KA; Ward WE; Chen JM; Saarinen NM; Thompson LU
Bone; 2006 Jul; 39(1):117-24. PubMed ID: 16469549
[TBL] [Abstract][Full Text] [Related]
28. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
31. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.
Dunstan CR; Felsenberg D; Seibel MJ
Nat Clin Pract Oncol; 2007 Jan; 4(1):42-55. PubMed ID: 17183355
[TBL] [Abstract][Full Text] [Related]
32. The fate of bone after renal transplantation.
Brandenburg VM; Westenfeld R; Ketteler M
J Nephrol; 2004; 17(2):190-204. PubMed ID: 15293518
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
34. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
[TBL] [Abstract][Full Text] [Related]
35. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
36. A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone.
Lau CP; Wong KC; Huang L; Li G; Tsui SK; Kumta SM
Connect Tissue Res; 2015 Nov; 56(6):493-503. PubMed ID: 26327464
[TBL] [Abstract][Full Text] [Related]
37. [Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice].
Ma XY; Li S; Luo DF; Liu RH; Lu YP; Wang SX; Ma D; Xi L
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):737-41. PubMed ID: 24378093
[TBL] [Abstract][Full Text] [Related]
38. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
39. In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
Wang Y; Lin B
Bone; 2013 Jul; 55(1):132-49. PubMed ID: 23416846
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Agyin JK; Santhamma B; Roy SS
Bioorg Med Chem Lett; 2013 Dec; 23(23):6455-8. PubMed ID: 24119559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
